Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Dunham Dynamic Macro N DNAVX Fund Analysis
Morningstar’s Analysis DNAVX
Will DNAVX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar